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HO-001: BIWEEKLY DOCETAXEL/CISPLATIN VS GEMCITABINE/
CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONS-
MALL CELL LUNG CANCER PATIENTS WHO ARE ELDERLY OR 
POOR PERFORMANCE STATUS: RANDOMIZED MULTICENTER 
PHASE II TRIAL
Hun Kyo Kim1, Joung Soon Jang2, Byoung Chul Cho3, Hongseok Song4, Hwan Jung Yun5, 
In Sook Woo6  
1Internal Medicine, Catholic University Hospital, Suwon/KOREA, 2Internal Medicine, 
Chung-Ang University Hospital, Seoul/KOREA, 3Division Of Medical Oncology, Yonsei 
Cancer Center, Seoul/KOREA, 4Internal Medicine, Keimyung University Hospital, 
Daegu/KOREA, 5Internal Medicine, Chungnam National University Hospital, Daejeon/
KOREA, 6Division Of Oncology, Department Of Internal Medicine, Yeoido St. Mary’s 
Hospital/KOREA
Background: Docetaxel/Cisplatin (DP) and Gemcistabine/Cisplatin (GP) are standard 
treatment regimens for advanced NSCLC. In spite of potent efficacy, conventional one-
day DP is regarded to have more toxicity compared with GP. There is increasing interest 
in a biweekly split administration of DP to reduce its toxicity. Hypothesis was that 
1st-line biweekly DP is as safe as GP in elderly or poor performance status (PS) patients 
(pts).  Methods: Chemotherapy naïve pts with advanced NSCLC (IIIB/IV) who were 
elderly(65<) or PS (ECOG 2) were randomized to DP or GP arm by balancing for ECOG 
(0-1 v. 2), stage (IIIB v. IV) and age (<65 v. 65<). DP comprosed of docetaxel (35mg/m2)/
cisplatin(30mg/m2) iv on days 1,8 every 3 weeks . GP comprosed of gemcitabine(1000mg/
m2)/cisplatin(30mg/m2) iv on days 1,8 every 3 weeks . Chemotherapy lasted upto 6 cycles 
or until progression. Primary endpoint was safety (proportion of grade 3/4 toxicities). 
Planned sample size was 49 pts in each arm.  Results: From Nov. 09 to Apr. 12, a total 
of 89 pts were randomized (DP 45/GP 44). Adenoca was 59% in DP arm and 50% in GP 
while that of squamous cell ca 34% in DP and 41% in GP. Stage IIIB/IV was 31%/67% 
in DP and 41%/59% in GP. In DP arm, a total 228 adverse events (AEs) were reported 
and 27 were grade 3/4 toxicities while 211 AEs and 21 grade 3/4 toxicities in GP arm. 
Neutropenia was the most frequent grade 3/4 toxicity in both arm (DP 8.9%; GP 15.9%). 
In DP arm, grade 3/4 leukopenia(8.9%), hyponatremia(6.7%), anemia(4.4%) and anorexia 
(4.4%) were observed while anemia (9.1%) and hyponatremia (6.8%) in GP. In total 
AEs, anemia was the most common in both arms (DP:66.7% ; GP:63.6%). Then, in the 
following order, hyponatremia (53.3%), anorexia (53.3%) and fatigue(40%) were common 
in DP arm while anorexia, (56.8%), fatigue(36.4%) and neutropenia(45.5%) were 
common in GP. Death during treatment was occurred in 1 pt in each arm. Both regimen 
showed similar grade 3/4 toxicities with similar profiles.  Conclusion: This study showed 
that DP is similar with GP in terms of efficacy and toxicity in treatment of elderly or poor 
performance patients.
Keywords: 1 non-small-cell lung cancer (NSCLC), 2. poor perfomance status, 3. elderly, 
docetaxel and cisplatin
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HO-002: RANDOMIZED PHASE III TRIAL OF S-1 PLUS CISPLATIN 
VERSUS DOCETAXEL PLUS CISPLATIN FOR ADVANCED NON-
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Background: Quality of life (QOL) should be an explicit priority throughout the course 
of care for patients with advanced non-small-cell lung cancer (NSCLC). Docetaxel plus 
cisplatin (DP) is the only third-generation regimen that has demonstrated statistically 
significant improvements in overall survival and QOL by a head-to-head comparison 
with a second-generation regimen (vindesine plus cisplatin) in patients with advanced 
NSCLC. A recent phase III study showed that S-1 plus carboplatin is noninferior to 
paclitaxel plus carboplatin in terms of overall survival (OS) as first-line treatment in 
patients with advanced NSCLC. Although S-1 plus cisplatin (SP) has shown activity and 
good tolerability in phase II settings, it is controversial as a cisplatin-based regimen.  
Methods: A total of 608 patients with stage IIIB or IV NSCLC were randomly assigned 
to receive either oral S-1 80 mg/m2/day (40 mg/m2 b.i.d.) on days 1 to 21 plus cisplatin 60 
mg/m2 on day 8 every 5 weeks or docetaxel 60 mg/m2 on day 1 plus cisplatin 80 mg/m2 
on day 1 every 3 weeks, both up to 6 cycles. The study included patients with ECOG PS 
of 0-1, an age of 20-74 years, and preserved organ functions. The primary endpoint was 
overall survival (OS). A noninferiority study design was employed; the upper confidence 
interval (CI) limit of the hazard ratio (HR) was <1.322. Secondary endpoints included 
progression-free survival (PFS), response, safety, and QOL. Patients filled in EORTC 
QLQ-C30 and LC13 questionnaires three times: before each treatment, 1 week after the 
first dose of cisplatin, and at end of the second course. QOL analysis was performed 
using repeated-measures analysis of variance.  Results: From April 2007 through 
December 2008, 608 patients were randomly assigned to SP (n=303) or DP (n=305) at 
66 sites in Japan. Patient demographics were well balanced between the two groups. 
Two interim analyses were preplanned. At the final analysis, a total of 480 deaths had 
occurred. The primary endpoint was met. OS in the SP arm was noninferior to that in the 
DP arm (median survival, 16.1 vs. 17.1 months, respectively; HR=1.013; 96.4% confidence 
interval, 0.837-1.227). PFS was 4.9 months in the SP arm and 5.2 months in the DP arm. 
The rates of febrile neutropenia (7.4% vs. 1.0%), grade 3/4 neutropenia (73.4% vs. 22.9%), 
grade 3/4 infection (14.5% vs. 5.3%), and grade 1/2 alopecia (59.3% vs. 12.3%) were 
significantly lower in the SP arm than in the DP arm. In terms of physical functioning 
and global functioning on the EORTC QLQ-C30 and LC-13 questionnaires, QOL was 
worse in the DP arm (p<0.01). Furthermore, the symptom scales of fatigue, nausea and 
vomiting, pain, insomnia, appetite loss, and diarrhea were worse in the DP arm (p<0.01).  
Conclusion: SP was noninferior to DP in terms of OS and had a better QOL, indicating 
that S-1 plus cisplatin is a standard first-line chemotherapeutic regimen for advanced 
NSCLC.
Keywords: non-small cell lung cancer, chemotherapy, cisplatin, S-1
HIGHLIGHTS OF ORAL PRESENTATION - November 28, 2012 11:00-12:30
HO-003: LUX-LUNG 3: AFATINIB VERSUS CISPLATIN AND PEME-
TREXED IN ASIAN PATIENTS WITH ADENOCARCINOMA OF 
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Background: Afatinib is a selective, orally bioavailable, irreversible ErbB Family Blocker 
of epidermal growth factor receptor (EGFR [ErbB1]), HER2 (ErbB2) and ErbB4. In a 
global study investigating the efficacy and safety of afatinib vs. cisplatin/pemetrexed 
in 345 patients with EGFR mutation-positive advanced stage lung adenocarcinoma, 
afatinib significantly prolonged progression-free survival (PFS) vs. cisplatin/pemetrexed 
(median 11.1 vs. 6.9 months, hazard ratio [HR]=0.58; p=0.0004) in the overall 
population and in patients with Del19/L858R mutations (median 13.6 vs. 6.9 months, 
HR=0.47; p<0.0001). Significant improvement in secondary endpoints of objective 
response rate (ORR) and delay in worsening of cancer-related cough and dyspnoea were 
reported for afatinib. Adverse events (AEs) observed were manageable. Here we present 
the results of a preplanned efficacy analysis for the Asian population and summarize 
the safety data.  Methods: As part of this global trial, 249 patients from Hong Kong, 
Japan, Korea, Malaysia, Philippines, Taiwan and Thailand (Stage IIIB/IV, performance 
status 0–1, chemo-naïve) were randomized 2:1 to oral daily afatinib 40 mg (n=166) or 
intravenous cisplatin/pemetrexed (75 mg/m2 + 500 mg/m2 every 21 days up to 6 cycles, 
n=83). The primary endpoint was PFS by central independent review.  Results: Baseline 
characteristics were balanced in both arms: median age, 61 years; female, 65%; never-
smoker, 70%; patients with Del19/L858R mutations, 92%. Significant improvement in 
PFS was observed in the overall Asian subgroup treated with afatinib vs. chemotherapy 
(median PFS of 11.3 vs. 6.9 months respectively, HR=0.54; p=0.0003) as well as in 
those with common mutations Del19 and L858R (n=224; 13.6 vs. 6.9 months, HR=0.44; 
p<0.0001). ORR was significantly higher with afatinib (63% vs. 21%; p<0.0001), with 
median duration of response 11.2 vs. 4.2 months, respectively. Most common severe 
(Grade 3) drug-related AEs were diarrhoea (16%), paronychia (14%) and rash (13%) with 
afatinib, and neutropenia (Grade 3, 15%; Grade 4, 4%), leucopenia (11%) and fatigue 
(6%) with cisplatin/pemetrexed. Drug-related AEs led to discontinuation in 9% of 
afatinib patients (including three patients with interstitial lung disease-like events and 
one patient with diarrhoea) and 11% of cisplatin/pemetrexed patients.  Conclusion: In 
an Asian subgroup, treatment with afatinib significantly prolonged PFS compared with 
cisplatin/pemetrexed, with significant improvement in secondary endpoints. The AE 
profile in Asian patients was consistent with safety findings in the overall population and 
with known safety profiles of both treatments. AEs with afatinib were manageable with a 
low discontinuation rate. With 4.4 months improvement in median PFS over the best-
in class chemotherapy comparator, afatinib is a clinically relevant first-line treatment 
option for Asian patients with EGFR mutation-positive lung cancer.
Keywords: afatinib, EGFR mutation, Asian, pemetrexed/cisplatin
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Background: Crizotinib is a novel orally available tyrosine kinase inhibitor targeting 
anaplastic lymphoma kinase (ALK). In early-phase testing, crizotinib was associated 
with an objective response rate (ORR) of 61% and a median progression-free survival 
(PFS) of 9.7 months in patients with advanced non-small cell lung cancer (NSCLC) 
harboring ALK gene rearrangements. In the present phase III study, we compared the 
efficacy and safety of crizotinib versus standard chemotherapy (pemetrexed or docetaxel) 
as second-line therapy for patients with advanced ALK-positive NSCLC.  Methods: 
Patients with stage IIIB/IV ALK-positive NSCLC previously treated with one prior 
platinum-based regimen (N=347) were randomized to receive crizotinib 250 mg PO BID 
(n=173) or chemotherapy (n=174; 57% pemetrexed 500 mg/m2; 41% docetaxel 75 mg/
m2; both IV q3w) between February 2010 and February 2012. ALK was detected by FISH 
in a central laboratory. Patients with progressive disease on chemotherapy were offered 
crizotinib on PROFILE 1005. The primary endpoint was PFS based on independent 
radiologic review; secondary endpoints included ORR, overall survival (OS), safety, 
and patient-reported outcomes.  Results: The study met its primary objective by 
demonstrating the superiority of crizotinib over chemotherapy in prolonging PFS 
(median 7.7 vs. 3.0 months; HR 0.49; 95% CI 0.37−0.64; P<0.0001). The ORR with 
crizotinib was significantly higher than with chemotherapy (65% vs. 20%; P<0.0001). 
In an interim analysis of OS (28% events), no statistically significant difference was 
found between crizotinib and chemotherapy (preliminary median estimate 20.3 vs. 22.8 
months; HR 1.02; 95% CI 0.68−1.54; P=0.539), but no adjustment had been made for 
crossover (111 patients [64%] crossed over to crizotinib). The most common all-causality 
adverse events (AEs) with crizotinib were diarrhea (60%), visual disturbance (60%), 
nausea (55%), vomiting (47%), and constipation (42%), while the most common all-
causality AEs with chemotherapy were nausea (37%), fatigue (33%), decreased appetite 
(26%), constipation (23%), and neutropenia (23%). The incidence of all-causality grade 
3/4 AEs was 56% for crizotinib and 46% for chemotherapy. The incidence of all-causality 
AEs leading to discontinuation was 17% for crizotinib and 13% for chemotherapy. 
Duration of treatment was longer in the crizotinib arm than in the chemotherapy 
arm (median cycles started 11 vs. 4).  Conclusion: Significant improvements in PFS 
and ORR were achieved with crizotinib compared with chemotherapy, and crizotinib 
demonstrated an acceptable safety profile. These findings establish crizotinib as the 
standard of care for patients with previously treated advanced ALK-positive NSCLC.
Keywords: crizotinib, phase III, ALK, LUNG CANCER
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HO-005: TREATMENT OF ALK-POSITIVE NON-SMALL CELL LUNG 
CANCER PATIENTS WITH CRIZOTINIB BEYOND DISEASE PRO-
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MENT IMPLICATIONS
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Background: Crizotinib is a first-in-class oral anaplastic lymphoma kinase (ALK) 
inhibitor that has been approved for the treatment of advanced ALK-positive non-
small cell lung cancer (NSCLC) in several countries. Despite the dramatic activity of 
crizotinib in ALK-positive NSCLC, the disease eventually progresses.  Methods: In two 
multicenter, single-arm trials (PROFILE 1001 and PROFILE 1005), patients with ALK-
positive NSCLC who had investigator-defined progressive disease (PD) on crizotinib 
were allowed to continue crizotinib treatment if there was reasonable evidence of 
ongoing clinical benefit in the investigator’s opinion. Clinical characteristics of these 
patients were assessed for the current analysis. A period of >2 weeks was chosen as a 
reasonable minimum duration of post-PD crizotinib treatment and was used as the 
cut-off for defining crizotinib treatment beyond PD.  Results: As of January 2012, among 
410 patients in the two studies, 229 patients had investigator-defined PD on crizotinib 
(All-PD group). PD was also determined using Response Evaluation Criteria in Solid 
Tumors (RECIST) in 97% of these 229 patients at some point during the study (in 3% 
of patients, PD either did not qualify as such per RECIST, or data were inadequate for 
such an assessment). Sixty percent of patients (138/229) received crizotinib beyond PD 
(CBPD group). Demographic characteristic were comparable between the All-PD and 
CBPD groups. Patients in the CBPD group tended to have a good Eastern Cooperative 
Oncology Group performance status (ECOG PS) both at baseline (ECOG PS 0/1, 85%; 
2/3, 15%) and at the time of PD (ECOG PS 0/1, 94%), and had a robust response to 
crizotinib (objective response rate, 70%) before PD. The median duration of post-PD 
treatment was 20 weeks (95% CI, 17−29). Thirty percent of patients in the CBPD group 
received treatment for >6 months. In the CBPD group, approximately half of new PD 
was due to new lesions and/or progression in non-target lesions only (new lesions only, 
26%; new lesions plus non-target lesions, 22%). Target-lesion-only PD occurred in 17% 
of patients. Only 12% of patients had global progression (ie, progression as new lesions 
and in both non-target and target lesions). The most common organ sites of new lesions 
or non-target-lesion progression were brain (46%), liver (26%), and lung (20%). Among 
36 patients with PD in new lesions only, the sites involved most commonly were brain 
(53%), bone (14%), and liver (14%).  Conclusion: Following initial crizotinib treatment, 
60% of patients received crizotinib as single-agent treatment post PD. The majority of 
patients receiving crizotinib post-PD had a good ECOG PS and a prior tumor response 
on crizotinib; these patients also tended to have new lesions as a source of new PD 
(most often in the brain or liver). “Crizotinib progressors” constituted a clinically 
heterogeneous subgroup of patients, a majority of whom were able to continue with 
crizotinib for a significant period of time following clinical or documented progression.
Keywords: ALK-positive NSCLC, post-PD, crizotinib
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Background: Inhibition of Hsp90, a key molecular chaperone required for activation 
of many oncoproteins, can lead to cancer cell death. Ganetespib (G) is a 2nd generation 
Hsp90 inhibitor that is devoid of the serious ocular and liver seen with other Hspi, and 
has shown single agent clinical activity in patients with ALK, KRAS, HER2, and BRAF 
mutations. G also inhibits pathways known to enhance sensitivity to taxanes, including 
hypoxia pathways (HIF-1) as well as cell-cycle and DNA repair pathways. Combination 
of G with docetaxel (D) results in synergistic activity in NSCLC xenografts and was well 
tolerated in a Phase I study. A first interim analysis of the Phase 2b stage of the GALAXY 
trial was conducted in June at approximately 50% enrollment. A second interim analysis 
was planned at approximately 80% enrollment. Results from the second interim analysis 
will be presented.  Methods: The GALAXY trial is an international, randomized 
Phase IIB/III study evaluating G plus D vs. D as 2nd line treatment of advanced NSCLC 
patients. The study is based on a two-stage, operationally adaptive design. The first-
stage, randomized, open-label, Phase 2b portion of the trial is designed to enroll Stage 
IIIB/IV NSCLC patients with adenocarcinoma histology (n=240) who have progressed 
following one prior line of therapy, with the goal of determining biomarkers predictive 
of ganetespib activity. Results will be used to guide choice of patient population for 
the Phase 3 stage of the trial. All patients receive D 75 mg/m2 on day 1 of a three-week 
treatment cycle; combination arm patients receive G 150 mg/m2 on day 1 and day 15 in 
addition. The co-primary endpoints of GALAXY are PFS (progression-free survival) 
in patients with elevated baseline level of serum LDH (lactate dehydrogenase), and PFS 
in the mutant KRAS population. PFS and OS (overall survival) in all adenocarcinoma 
patients are key secondary endpoints. Serum LDH levels and tumor KRAS mutation 
status are assessed by independent central laboratories.  Results: At the time of the June 
2012 first interim analysis, a total of 114 adenocarcinoma and 69 non-adenocarcinoma 
patients had been enrolled. Baseline characteristics were balanced. The overall safety 
profile of the combination was generally comparable to single agent docetaxel. Early 
signals of activity were observed in the two pre-specified patient populations, elevated 
baseline serum LDH and mutant KRAS, as well as in the all adenocarcinoma patient 
population. Results from the second planned interim analysis will be presented at this 
meeting.  Conclusion: Ganetespib in combination with docetaxel was well tolerated by 
patients with advanced NCSLC. Encouraging signals of activity in the primary endpoint 
patient populations have been observed and have been used to inform the design of the 
Phase 3 stage of the trial.
